Biopharma organizations struggle with multimodal data analysis complexity

"Life sciences data has always been inherently multimodal. Consider how a single cell can yield data that crosses modalities ranging from transcriptomics to spatial imaging to metabolomics. Zooming out to the level of human health, we can add data types from population genomics, clinical trial results, remote monitoring sensors and EHRs .... .... In this blog post, we review high-level findings from surveys and interviews as well as explore ... [corresponding] issues and opportunities of multimodal data in life sciences. "

Fragmented technology stacks are preventing organizations from achieving unified multimodal analysis. Our survey revealed that biopharma teams require platforms that integrate all project data assets into a single space for seamless analysis. 📖 From our latest report: 𝘛𝘩𝘦 𝘚𝘵𝘢𝘵𝘦 𝘰𝘧 𝘔𝘶𝘭𝘵𝘪𝘮𝘰𝘥𝘢𝘭 𝘋𝘢𝘵𝘢 𝘪𝘯 𝘉𝘪𝘰𝘵𝘦𝘤𝘩 & 𝘗𝘩𝘢𝘳𝘮𝘢 2025 https://hubs.la/Q03N41CL0

Pharma's productivity crisis is accelerating. Eroom's Law shows the industry is getting HALF the drugs per billion invested every 9 years. On Tuesday, 7 October at BioTechX Europe, our GM Simon Meffan-Main will reveal how leading biopharma companies are finally reversing this trend through industrial-scale scientific data management. The breakthrough: 90% of biopharma data challenges are common problems requiring common solutions. Instead of DIY projects adding to what's already 10+ million data silos, the industry needs a Foundry + Factory model that industrializes scientific workflows. What attendees will discover:  • Universal SDMS delivering 30% faster cycle times  • AI-native data architecture enabling 25% productivity gains  • The emergence of "Sciborgs" - scientists who think like data engineers Join us for the keynote to learn how industry leaders are driving the pharma industrial revolution. Stop by booth #611 to meet with Simon and the TetraScience team at #BioTechX. Book a meeting here: https://lnkd.in/eMkCBTYk

What will it take for America to stay competitive in biotech innovation? In his new article, Dr. Scott Gottlieb—former FDA Commissioner and WWSG exclusive speaker—explains how Chinese biotech firms are changing the market and why the U.S. must update FDA frameworks, speed up early trials, and use AI to stay competitive. Contact WWSG today to bring Dr. Gottlieb’s expert insights to your next conference or event. Read the full article here: https://hubs.ly/Q03KwJMY0

In pharma, speed without rigour is risky ⚡ Biostatistics is how teams move faster and stay safe - optimizing study design, integrating real-world data, and using advanced models for smarter, earlier decisions. With global medicine spend rising and demand accelerating, the edge belongs to those who turn data into evidence. Read more on our blog 👉 https://lnkd.in/e6tXJ37F #Akkodis #Biostatistics #Innovation #Safety

This week at BioTechX Europe, expert.ai unveiled new AI-powered solutions designed to accelerate innovation across Pharma & Life Sciences. “Our enhanced solutions are purpose-built to accelerate decision making and shorten regulatory review timelines. By uncovering real-world evidence from scientific literature and clinical trial data, professionals and researchers can bring effective drugs and treatments to patients faster.” - Christophe Aubry, Global Head of Life Sciences & Healthcare, Expert.ai. 👋 Visit Booth #515 to meet Christophe and the team to discover how our hybrid AI approach is helping organizations turn data into smarter science. ➡️ Learn more about the new solutions here: https://lnkd.in/eU24xVNG

📄 Seizing the momentum: a joint call for AI Factories in Belgium to boost life sciences AI has the potential to transform every stage of the pharmaceutical life cycle. Its impact spans from research and development to manufacturing. To unlock this potential, the sector needs long-term infrastructure, clear adoption strategies and close collaboration between industry and academia. These themes were discussed during a recent CIONET x LCL Data Centers roundtable, where I joined leaders from GSK, Johnson & Johnson and UCB. The session was led by Prof. Stein Aerts from VIB.AI. A key opportunity that emerged was the European Commission’s AI Factories initiative. These Factories will act as dynamic hubs, bringing together supercomputing power, data, and attract talent to develop cutting-edge, trustworthy AI software. Curious to dive deeper? This whitepaper distils the key insights from the roundtable and makes the case for Belgium to take the lead in housing AI infrastructure that supports life sciences, and safeguards European competitiveness. 👉 Take your seat at the table and download the whitepaper: https://hubs.ly/Q03N5KBY0 #LCLDataCenters #CIONET #Pharma #Biotech #AI #AIFactories

The Tech market feels overpriced and reminds me of 2000/2001 in dot com. The only difference is that today the bubbles are massive companies with hundreds of thousands of employees who are now multi millionaires. At the same time, the Biotech market is bottoming. What I am afraid of is what happens with biotech after the AI wave goes down. In my opinion, we need to build the operational and organizational resilience to sustain the long biotech winter and have a good mix of high-novelty programs with a mix of high-confidence/high commercial-tractability programs. At the same time, we must race toward the pharmaceutical superintelligence (PSI) to be able to operate in maximally-automated mode regardless of what happens to the markets.

📄 Seizing the momentum: a joint call for AI Factories in Belgium to boost life sciences AI has the potential to transform every stage of the pharmaceutical life cycle. Its impact spans from research and development to manufacturing. To unlock this potential, the sector needs long-term infrastructure, clear adoption strategies and close collaboration between industry and academia. These themes were discussed during a recent CIONET x LCL Data Centers roundtable, where leaders from GSK, Johnson & Johnson and UCB joined the discussion. The session was led by Prof. Stein Aerts from VIB.AI. A key opportunity that emerged was the European Commission’s AI Factories initiative. These Factories will act as dynamic hubs, bringing together supercomputing power, data, and attract talent to develop cutting-edge, trustworthy AI software. This whitepaper distils the key insights from the roundtable and makes the case for Belgium to take the lead in housing AI infrastructure that supports life sciences, and safeguards European competitiveness. 👉 Take your seat at the table and download the whitepaper: https://hubs.ly/Q03N5Gk_0 #LCLDataCenters #CIONET #Pharma #Biotech #AI #AIFactories